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Abstract
 
The balance between pro and antiinflammatory cytokines secreted by T cells regulates both the
initiation and perpetuation of inflammatory bowel diseases (IBD). In particular, the balance be-
tween interferon (IFN)-
 
 
 
/interleukin (IL)-4 and transforming growth factor (TGF)-
 
 
 
 activity
controls chronic intestinal inflammation. However, the molecular pathways that evoke these
responses are not well understood. Here, we describe a critical role for the transcription factor
T-bet in controlling the mucosal cytokine balance and clinical disease. We studied the expression
and function of T-bet in patients with IBD and in mucosal T cells in various T helper (Th)1-
and Th2-mediated animal models of chronic intestinal inflammation by taking advantage of
mice that lack T-bet and retroviral transduction techniques, respectively. Whereas retroviral
transduction of T-bet in CD62L
 
 
 
 CD4
 
 
 
 T cells exacerbated colitis in reconstituted SCID
mice, T-bet–deficient T cells failed to induce colitis in adoptive transfer experiments suggesting
that overexpression of T-bet is essential and sufficient to promote Th1-mediated colitis in vivo.
Furthermore, T-bet–deficient CD62L
 
 
 
 CD4
 
 
 
 T cells showed enhanced protective functions in
Th1-mediated colitis and exhibited increased TGF-
 
 
 
 signaling suggesting that a T-bet driven
pathway of T cell activation controls the intestinal balance between IFN-
 
 
 
/IL-4 and TGF-
 
 
 
responses and the development of chronic intestinal inflammation in T cell–mediated colitis.
Furthermore, TGF-
 
 
 
 was found to suppress T-bet expression suggesting a reciprocal relation-
ship between TGF-
 
 
 
 and T-bet in mucosal T cells. In summary, our data suggest a key regula-
tory role of T-bet in the pathogenesis of T cell–mediated colitis. Specific targeting of this path-
way may be a promising novel approach for the treatment of patients with Crohn’s disease and
other autoimmune diseases mediated by Th1 T lymphocytes.
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Introduction
 
Crohn’s disease and ulcerative colitis are the two major
forms of inflammatory bowel diseases (IBD)
 
*
 
 in humans
(1–4). Whereas Crohn’s disease is characterized by a trans-
mural, granulomatous inflammation that can occur any-
where in the gastrointestinal tract, ulcerative colitis causes a
more superficial, continuous inflammation that is restricted
to the large bowel (5). Although the etiology of the diseases
is unknown, it has been suggested that an activation of the
mucosal immune system in response to bacterial antigens
with consecutive pathologic cytokine production and acti-
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vation of matrix metalloproteinases plays a key pathogenic
role (6–8). In particular, cytokines produced by T lympho-
cytes appear to initiate and perpetuate chronic intestinal in-
flammation (9–15). Interestingly, cytokine production by
lamina propria (LP) CD4
 
 
 
 T lymphocytes differs between
Crohn’s disease and ulcerative colitis. Whereas the former
disease is associated with increased production of Th1 type
cytokines such as IFN-
 
 
 
 and TNF, the latter disease is asso-
ciated with T cells producing large amounts of the Th2
type cytokine IL-5 while IFN-
 
 
 
 production is unaffected
(10, 13, 16). The proinflammatory function of both Th1
and Th2 cytokines in experimental models of IBD is coun-
teracted by the immunosuppressive cytokine TGF-
 
 
 
,
mainly secreted by Th3 cells and a unique population of
regulatory T cells (17–19).
Recent studies have focused on the molecular mecha-
nisms underlying Th1 and Th2 T cell development (20,
21). T lymphocytes transit through sequential stages of cy-
tokine activation, commitment, silencing, and physical sta-
bilization during polarization into differentiated effector
subsets, a process tightly controlled by regulatory transcrip-
tion factors (21–24). Various transcription factors such as
c-maf, GATA-3, NFATc1, NIP45, JunB, and signal trans-
ducer and activator of transcription (STAT)-6 have been
shown to induce or augment Th2 cytokine production, al-
though only c-maf and GATA-3 are expressed selectively
in Th2 cells (25–30). In particular, GATA-3 has been
shown to promote expression of several Th2 cytokines, in-
cluding IL-4, IL-5, and IL-13, either by transactivation of
cytokine gene promoters and enhancers or the induction of
chromatin remodelling (24, 27, 31–34). On the other
hand, STAT-1 and STAT-4 transcription factors are specif-
ically associated with IFN-
 
 
 
 and IL-12/IL-23 signaling in
T lymphocytes, respectively, and play a key role in regulat-
ing cytokine production of Th1 cells at the transcriptional
level (21, 35, 36).
However, the STAT proteins are expressed in both Th1
and Th2 subsets and may not have a major role in directly
regulating the transcription of the IFN-
 
 
 
 gene. Indeed,
some IFN-
 
 
 
 production is retained by STAT-4– and
STAT-1–deficient T cells (37, 38). Thus, it appears that al-
ternative regulatory pathways exist that control IFN-
 
 
 
gene expression. Recently a novel transcription factor of
the T-box family, denoted T-bet (39), has been cloned that
has shed light on the Th1-restricted expression of IFN-
 
 
 
.
T-bet has been found to be expressed by IFN-
 
 
 
–producing
Th1 but not Th2 cells and increased transcripts for T-bet
have been reported to occur within 72 h after stimulation
of T cells under Th1-inducing conditions (22, 39). Retro-
viral transduction of T-bet into primary developing T cells
or even fully polarized Th2 cells induces high levels of
IFN-
 
 
 
 production and simultaneously represses production
of IL-4 and IL-5 (39). T-bet thus appears to be a master
switch for Th1 T cell development and the regulation of T
cell effector function. Based on this observation, we ana-
lyzed in the present study the role of T-bet in regulating
cytokine production and clinical disease in chronic intesti-
nal inflammation. We demonstrate a critical role for this
 
factor in controlling IBD by regulating the cytokine bal-
ance in T cells.
 
Materials and Methods
 
Patients.
 
Gut specimens obtained from patients with Crohn’s
disease or control patients were studied. The Crohn’s disease
group (
 
n 
 
 
 
 21) consisted of 10 men and 11 women, ranging from
19 to 57 y of age. The diagnosis for each patient was made using
clinical parameters, radiographic studies, and histologic criteria.
At the time of sample collection, 12 patients of the Crohn’s dis-
ease group were receiving corticosteroids and three patients were
receiving an oral sulfasalazine preparation. The control group
consisted of colonic specimens from 23 patients. There were 12
male and 11 female patients in the control group ranging from 41
to 78 y of age. These patients were not receiving sulfasalazine or
corticosteroids at the time of the resection. In addition, colonic
sections from four patients with ulcerative colitis were obtained.
Collection of surgical samples was approved by the ethical com-
mittee and the institutional review board of the University of
Mainz.
 
Immunohistochemistry.
 
Immunohistochemistry was performed
on 7-
 
 
 
m cryosections from gut specimens of both control and
Crohn’s disease/ulcerative colitis patients, as described previously
(11, 40). Briefly, tissues were fixed in 4% paraformaldehyde/PBS
and washed in 0.01 M PBS. Samples were then pretreated with
10% of serum (corresponding to the secondary antibody) in PBS/
0.1% Triton-X and incubated overnight at 4
 
 
 
C with the primary
antibody (5–10 
 
 
 
g/ml monoclonal or polyclonal rabbit anti–
T-bet (39) or goat anti–GATA-3; obtained from Santa Cruz Bio-
technology, Inc.) in PBS/0.5% BSA/0.2% saponin. Samples with-
out primary antibody served as negative control. The following
day, samples were rinsed in PBS and incubated with a biotiny-
lated secondary IgG antibody (1:200 dilution; obtained from
Pierce Chemical Co.) for 1 h at room temperature followed by
incubation with streptavidin conjugated Cy2 or Cy3 (Dianova)
(1:500–1:1,000 dilution) for 1 h at room temperature. Samples
were rinsed with PBS and, in some experiments, subjected to a
second cycle of staining by using anti-CD3 as primary antibody
(monoclonal mouse anti–human CD3; BD PharMingen) and
streptavidin-conjugated Cy3 as chromogen (40). Slides were
mounted with DAPI-containing mounting medium for fluores-
cence (Vector Laboratories) and analyzed with a Olympus Micro-
scope. 6–10 high power fields (HPF) were finally counted in all
patients per condition. No staining was detected in samples with-
out primary antibody.
 
Isolation of Human LP T Cells.
 
LP mononuclear cells (LPMCs)
were isolated using a previously described technique (10). LP T
cells were prepared from the resultant cell population as described
previously (11). The resulting cells were 
 
 
 
90% T cells, as assessed
by FACS
 
®
 
 analysis (FACStar™; Becton Dickinson). The T cells
were either analyzed directly or cultured in complete media with
antibodies to human CD2 and CD28 (1 
 
 
 
g/ml; obtained from
BD PharMingen). Complete medium consisted of RPMI 1640
supplemented with 3 mM 
 
L
 
-glutamine, 10 mM Hepes buffer, 10
 
 
 
g/ml gentamycin (Whittaker), 100 U/ml each of penicillin and
streptomycin (Whittaker), 0.05 mM 2 ME (Sigma-Aldrich), and
10% heat-inactivated FCS.
 
Electrophoretic Mobility Shift Assays.
 
Oligonucleotides for elec-
trophoretic mobility shift assays (EMSAs) were synthesized, an-
nealed, and end-labeled with 
 
 
 
-[
 
32
 
P]-ATP (
 
 
 
6,000 Ci/mmol;
NEN Life Sciences Labs) using bacteriophage T4 polynucleotide
kinase (New England Biolabs Inc.). Synthetic, double-stranded 
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oligonucleotides containing binding sites for SP-1, AP-2, 
 
 
 
E5,
and GATA-3 for EMSA were obtained from Santa Cruz Bio-
technology, Inc. and MWG Biotech, respectively. The sequences
of T-bet binding sites have been described elsewhere (39). Bind-
ing reactions (15 
 
 
 
l) for EMSA contained 2 
 
 
 
g synthetic DNA
duplex of poly (dI-dC) (Amersham Pharmacia Biotech), 25,000
cpm (Cerenkov) of end-labeled DNA probe, and incubation
buffer (10 mM Hepes, pH 7.9, 100 mM NaCl, 10% glycerol, 0.5
mM MgCl
 
2
 
, 1 mM DTT). After preincubation for 15 min at
room temperature, radiolabeled DNA was added to the reaction
for an additional 15 min. 2 
 
 
 
g of the monoclonal anti–mouse
T-bet IgG1 (4B10; reference 39), a c-jun antibody (Santa Cruz
Biotechnology, Inc.) or a polypeptide T-bet antibody (H2N-CSD-
SGLGEGDTKRRRI-CONH2; obtained from Eurogentec) were
added as indicated. Finally, the complexes were separated from
unbound specific probe by electrophoresis on native 4% poly-
acrylamide gels. After electrophoresis, the gels were dried and ex-
posed to Kodak films on intensifying screens at 
 
 
 
80
 
 
 
C.
 
Western Blot Analysis.
 
For Western blot analysis, equal
amounts of extract (30 
 
 
 
g) were added to 10 
 
 
 
l electrophoresis
sample buffer. After boiling, the extracts were loaded on 10%
SDS-PAGE gels and electrophoretically separated for 2 h at 100 V.
Proteins were transferred to nitrocellulose membranes and de-
tection was performed with a polyclonal rabbit or monoclonal
mouse anti–T-bet (39), rabbit anti–mouse GATA-3, polyclonal
goat or rabbit anti-Smad3, goat anti-Smad7 (all obtained from
Santa Cruz Biotechnology, Inc.), and 
 
 
 
-actin antibodies (Sigma-
Aldrich), HRP-conjugated secondary antibodies (donkey anti–
rabbit Ig, obtained from Sigma-Aldrich; anti–goat IgG, obtained
from Santa Cruz Biotechnology, Inc.; anti–rat IgG, obtained
from Pierce Chemical Co.) and the ECL Plus or ECL Western
blotting analysis system (Amersham Pharmacia Biotech).
 
Animals.
 
2–4-mo-old Balb/c and B6 mice were obtained
from the central breeding facility at the University of Mainz or
from Charles River Laboratories; S129/B6 wild-type and STAT-
1–deficient mice (38) were obtained from Taconic; T-bet knock-
out mice and transgenic mice expressing T-bet in T cells under
the control of the CD2 promoter/enhancer construct have been
described previously (41, 42). B cell–deficient TCR-
 
 
 
 
 
/
 
 
 
/
 
 
 
 
 
/
 
 
 
mice and IL-10–deficient mice (4–12 wk old) with chronic en-
terocolitis have been described previously (43, 44). C.B.-17
SCID or recombination activation gene (RAG)-deficient mice
were obtained from Charles River Laboratories or Taconic.
 
Screening of T-bet Knockout Mice.
 
Tail DNA from mice was
isolated and subjected to polymerase chain reaction (PTC-100
Thermal Cycler; MJ Research Inc.) using three synthetic primers
(T-bet1 5
 
 
 
-GCG CGA AGG GGC CAC CAA AGA ACG
GAG-3
 
 
 
, T-bet2 5
 
 
 
-GAC TGA AGC CCC GAC CCC CAG
TCC TAA G-3
 
 
 
, T-bet3 5
 
 
 
-TGG GCA TAC AGG AGG CAG
CAA CAA ATA-3
 
 
 
; obtained from GIBCO BRL) and the Ad-
vantage PCR kit (CLONTECH).
 
Isolation of LPMCs.
 
LPMCs were isolated from freshly ob-
tained colonic specimens using a modification of the technique
described by van der Heijden and Stok, as described previously
(45). After removal of the Peyer’s patches, the colon was washed
in HBSS free of calcium and magnesium, cut in 3-mm pieces and
incubated twice in HBSS containing EDTA (0.35 mg/ml) and
DTT (0.145 mg/ml; both obtained from Sigma-Aldrich) at 37
 
 
 
C
for 15 min. Next, the tissue was digested further in RPMI 1640
containing collagenase D (400 U/ml) and DNase I (0.1 mg/ml)
(Boehringer Mannheim) in a shaking incubator at 37
 
 
 
C. LP cells
were then layered on a 40–100% Percoll gradient (Amersham
Pharmacia Biotech) and lymphocyte-enriched populations were
 
isolated from the cells at the 40–100% interface. In some experi-
ments, LPMCs were further enriched for T cells using cell adher-
ance to plastic dishes for 1 h at 37
 
 
 
C.
 
Cytokine Assays.
 
To measure cytokine production, 10
 
6
 
 splenic
T cells or 0.5–2 
 
 
 
 10
 
6
 
 T cell enriched LPMC per ml were ac-
tivated with 10 
 
 
 
g/ml purified hamster anti–mouse CD3
 
 
 
 (clone
145–2C11) and 1 
 
 
 
g/ml soluble hamster anti–mouse CD28
(clone 37.51) with or without IFN-
 
  
 
and cultured in complete
medium (RPMI 1640 supplemented with 3 mM 
 
L
 
-glutamine,
10 mM Hepes buffer, 100 U/ml penicillin/streptomycin, 0.05
mM 2 ME, 10% heat inactivated FCS) or serum-free medium at
37
 
 
 
C in a humidified atmosphere containing 5% CO
 
2
 
. After 48 h
(96 h for TGF-
 
 
 
), culture supernatants were removed and as-
sayed for cytokine concentration. Cytokine concentrations were
determined by specific ELISA using commercially available re-
combinant cytokines and antibodies (BD PharMingen, Genzyme
Corp., R&D Systems, and Boehringer Mannheim).
 
Retroviral Gene Transfer in Primary Splenic CD4
 
 
 
 T Lympho-
cytes.
 
For retroviral gene transfer of primary T cells the GFP-RV
vector and its derivates were used. The GFP-RV bicistronic vec-
tor was constructed by inserting the encephalomyocarditis virus
ribosomal entry sequence (IRES) and the GFP allele into the
MSCV2.2 retroviral vector (31, 32). The GFP-RV vector and
the GATA-3-GFP vector were donated by K. Murphy and the
Phoenix-Eco packaging cell line was obtained from G. Nolan
(46). The pGCIRES and pGCIRES.T-bet retroviral constructs
have been described previously (39).
Splenic CD4
 
 
 
 T cells from healthy Balb/c mice were isolated,
as described previously (11). In brief, spleens were aseptically re-
moved and washed thoroughly in HBSS free of calcium and
magnesium. The tissue was cut into small pieces and pushed
through a 40-
 
 
 
m nylon cell strainer (Falcon; Becton Dickinson).
Erythrocytes were removed from the resulting cell suspension by
hypotonic lysis in ACK buffer. Spleen cells were then washed in
PBS, centrifuged at 1,600 rpm for 10 min at 4
 
 
 
C and CD4
 
 
 
 T
cells were isolated using immunomagnetic beads and MACS
 
®
 
(Miltenyi Biotec). Cell purity was 
 
 
 
97%, as assessed by FACS
 
®
 
analysis. Retroviral infection of primary splenic CD4
 
 
 
 T cells
with polybrene (Sigma-Aldrich) and retroviral supernatants was
performed as described previously (32). The following day cells
were incubated with PE-labeled CD62L antibodies (BD Phar-
Mingen) and sorted by FACS
 
®
 
 (Becton Dickinson) to obtain
CD62L
 
 
 
 GFP
 
 
 
 double positive CD4
 
 
 
 T lymphocytes. Finally,
1–5 
 
  105 CD62L  GFP  CD4  T cells were injected in CB-17
SCID mice. SCID mice were maintained in isolated cages under
specific pathogen free conditions.
Adoptive Transfer of CD4  T Cell Subsets in Immunocompromised
Hosts. To induce colitis by adoptive transfer of CD4  T cells, a
modification of a previously described protocol was used (11, 17).
In brief, CD4  T cells were purified from spleen mononuclear
cells of healthy mice using FITC-conjugated mAbs, anti-FITC
immunomagnetic beads, and MACS® (Miltenyi Biotech), or
anti-CD4 beads (Dynal) followed by enzymatic removal of the
beads. The resulting CD4  T cells (purity  97%) were further
separated by immunomagnetic beads into CD62L  and CD62L 
T cells. The former cells (purity:  95%) showed high expres-
sion of CD45RB by FACS® analysis. 0.5–1   106 CD62L 
CD45RBhigh CD4  T cells or 106 CD62L  CD45RBhigh and
CD62L  (ratio 1:4) CD4  T cells were finally transferred into
C.B.-17 SCID or RAG-1–deficient mice. Colitis activity was
monitored by weight curves, endoscopy and histologic analysis, as
specified below. Mice were maintained in isolated cages under
specific pathogen free conditions. No evidence of graft versus1132 T-bet in Chronic Intestinal Inflammation
host disease, such as skin inflammation and histopathologic evi-
dence of small bowel inflammation, was observed in the reconsti-
tuted animals under our experimental conditions.
Induction of Colitis by Haptenizing Agents. Oxazolone-induced
colitis in S129/B6 mice was induced using a modification of pre-
viously described method (47), as this mouse strain exhibits in-
creased resistance to inducible colitis by hapten reagents (6). In
brief, mice were sensitized by epicutaneous application of 3%
oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one; ob-
tained from Sigma-Aldrich) in 100% ethanol (150  l) on day 0
followed by intrarectal administration of 1% oxazolone in 50%
ethanol (100  l) to anesthetized mice on day 7.
Treatment of Mice with Neutralizing Antibodies to IL-4. In some
experiments, colitic mice were treated with neutralizing antibod-
ies to IL-4 (11B.11; 7 mg/wk; obtained from the Biological Re-
sources Branch, DCTD, Frederick, MD, as specified in Results).
Assessment of Contact Hypersensitivity. Contact hypersensitiv-
ity after oxazolone sensitization was assessed on day 7, essentially as
described by Xu et al. (48). In brief, ear swelling before and 24 h
after ear challenge with 1% oxazolone in 100% ethanol (vol: 20  l)
was determined using a dial thickness gauge (Mitutoyo). The
DTH responses were expressed as percentage increase in ear thick-
ness after oxazolone challenge over the baseline values (100%).
Histologic Analysis of Colon Cross Sections. Tissues were re-
moved from colitic mice at indicated time points, and cryosec-
tions or paraffin sections were made and stained with hematoxy-
lin and eosin. For colitis induced by CD62L  CD4  T cell
transfer, the degree of inflammation and epithelial injury on mi-
croscopic cross sections of the colon was graded semiquantita-
tively from 0 to 4: inflammation score 0   no evidence for in-
flammation; 1   low level of inflammation with scattered
infiltrating mononuclear cells (1–2 foci only); 2   moderate in-
flammation with multiple foci; 3   high level of inflammation
with increased vascular density and marked wall thickening; and 4
  maximal severity of inflammation with transmural leukocyte
infiltration and loss of goblet cells. Injury score 0   no epithelial
injury; 1   occasional epithelial lesion; 2   1–2 foci of ulcer-
ations; and 3   extensive ulcerations. Grading of colitis activity
was done in a blinded fashion by the same pathologist (J. Glick-
man). Small bowel sections were taken from some animals as an
additional control and showed no evidence for inflammation.
For histopathologic grading of oxazolone-induced colitis five
criteria (hypervascularization, presence of mononuclear cells, epi-
thelial hyperplasia, epithelial injury, and presence of granulocytes)
were scored from 0 to 3 yielding an additive score between 0 (no
colitis) and 15 (maximal colitis activity).
In Vivo Endoscopic Analysis of the Colon. A novel method was
developed to perform endoscopy in mice using a mini-endoscope
(length: 30 or 60 mm, diameter: 0.89 mm) with an intralux vision
light source (Volpi AG, Switzerland and Insight Instruments)
(unpublished data). In brief, mice were anesthetized with avertine
and the colon was flushed with PBS. Prominent endoscopic signs
of inflammation in SCID mice were masking of the normal vas-
cular pattern, the presence of mucosal granularity, and the ap-
pearance of ulcers. Based on our data in  100 endoscopies in
colitic SCID/RAG mice a murine endoscopic index of colitis se-
verity (MEICS) was developed that consists of the following four
criteria: ulcerations, none: 0, 1–2: 1, 3–5: 2,  5: 3 points   2;
masking of the normal vascular pattern: none: 0, moderate: 1,
marked: 2, complete or almost complete: 3 points; mucosal gran-
ularity: none: 0, moderate: 1, marked: 2, extreme: 3 points; and
surface involved in cm: none: 0, 1–2: 1, 3–4: 2,  4: 3 points.
The cumulative MEICS score was between 0 and 15 points. This
index allows monitoring of colitis activity in individual SCID/
RAG mice over several months, as the endoscopic procedure can
be repeated without problems for up to eight times. To deter-
mine colitis activity in reconstituted SCID or RAG mice the
mice were monitored by endoscopy at indicated time points after
the cell transfer.
FACS® Analysis and Staining for T-bet and STAT-1. FACS®
analysis of splenic and LP cells was performed as described previ-
ously (11). Antibodies against murine CD4 (Cychrome) and CD25
(FITC) were obtained from BD PharMingen. Intracellular staining
for T-bet was performed as described previously (39). Intracellular
staining for STAT-1 was done using the same method and anti–
human STAT-1 antibodies (Santa Cruz Biotechnology, Inc.).
Statistical Analysis. Statistical analysis was made using the Stu-
dent’s t test and the program Statworks for Macintosh and MS
Office (Excel).
Results
Reciprocal Expression of GATA-3 and T-bet in LP T Cells
from Patients with Crohn’s Disease. Changes in cytokine
production by LP T cells have been implicated as a key
phenomenon in the pathogenesis of IBD. In particular, an
increased production of Th1 (such as IFN-  and TNF) cy-
tokines is present in patients with Crohn’s disease, while
ulcerative colitis is associated with production of high levels
of the Th2 cytokine IL-5 (9–11, 13). Interestingly, a novel
transcription factor of the T box family, denoted T-bet, has
been recently shown to control both IFN-  and IL-5 pro-
duction (39). Therefore, we focused in an initial series of
experiments on the expression of T-bet by purified LP T
cells in IBD patients. Immunofluorescence double staining
studies showed an accumulation of T-bet expressing LP T
cells in patients with Crohn’s disease (Fig. 1 A–D). In addi-
tion, it was found that T-bet was strongly expressed in both
the cytoplasm and the nucleus of LPMCs in patients with
Crohn’s disease, while only a weak staining in perinuclear
areas or no staining was observed in control patients and
patients with ulcerative colitis (Fig. 1 E). To verify these
data on increased expression of T-bet in patients with
Crohn’s disease, we isolated nuclear extracts of purified LP
T cells from patients with Crohn’s disease and control pa-
tients and analyzed expression of T-bet by EMSA and
Western blot analysis. We observed that patients with
Crohn’s disease expressed higher amounts of nuclear T-bet
compared with control patients (Fig. 2 A–C). This obser-
vation was supported by intracellular FACS® staining of
cells for T-bet demonstrating strongly increased T-bet lev-
els in Crohn’s disease patients compared with controls (Fig.
2 D). Similarly, the expression of the IFN-  associated
transcription factor STAT-1 was upregulated in Crohn’s
disease compared with control patients, although to a much
lesser extent (Fig. 2 D).
Next, we assessed the expression of GATA-3 in LP T
cells from Crohn’s disease patients, since this transcription
factor has been shown to directly transactivate the IL-5 pro-
moter and to mediate Th2 effector function (27, 32). We
observed that GATA-3 expression was downregulated in LP
T cells from Crohn’s disease patients compared with control1133 Neurath et al.
patients, as assessed by immunohistochemical double stain-
ing analysis for CD3 and GATA-3 on colon cryosections
(Fig. 1 F). Taken together, these data suggested a reciprocal
expression pattern of GATA-3 and T-bet in Crohn’s disease
LP T cells that is associated with increased IFN-  but de-
creased IL-4 and IL-5 production in this disease.
Induction of T-bet Expression in Th1- but not Th2-mediated
Animal Models of Chronic Intestinal Inflammation. Since the
above data were consistent with the possibility of a regula-
tory role for T-bet in controlling cytokine production in
Figure 1. Accumulation of T-bet–expressing T lymphocytes in the LP of
patients with Crohn’s disease. (A and B) Analysis of T-bet expression in the
LP from patients with IBD and control patients. Colon cryosections were
stained with a T-bet antibody and sections were analyzed by immunofluo-
rescense microscopy and confocal laser microscopy, respectively. Many
T-bet positive cells were seen in patients with Crohn’s disease but not ulcer-
ative colitis. Data are representative of four to five patients per group. (C)
Immunohistochemical double staining analysis of the cellular expression of
T-bet plus CD3 in consecutive cross sections. Cryosections from patients
with Crohn’s disease (n   10), ulcerative colitis (n   4) and control patients
(n   8) were stained with antibodies to CD3 and T-bet, as indicated. One
representative experiment is shown. Double positive cells are indicated by
arrows. (D) Quantitative analysis of T-bet-positive CD3  LP T cells in pa-
tients with Crohn’s disease, ulcerative colitis, and control patients. The per-
centage of double-positive T cells in four to six patients per group was quan-
tified as specified in Materials and Methods. Data represents mean values  
SD. (E) Analysis of T-bet expression by LPMCs from patients with Crohn’s
disease and control patients. Nuclei were counterstained with DAPI, as spec-
ified in Materials and Methods. Most T cells from control patients showed
weak expression of T-bet in perinuclear areas, whereas high cytoplasmic and
nuclear expression was noted in patients with Crohn’s disease. (F) Double
staining analysis for GATA-3 and CD3 in the LP of patients with Crohn’s
disease (CD) and control patients (con), as indicated. Colon cryosection
were stained with a polyclonal anti–GATA-3 antibody and anti-CD3 anti-
bodies. There was a marked reduction of GATA-3 expression in LP T cells
from patients with Crohn’s disease compared with control patients. Data are
representative of four to six patients per group. Cytospins from PMA- plus
ionomycin-stimulated peripheral blood T cells served as a positive control.
Figure 2. Increased nuclear expression of T-bet in LP T cells from pa-
tients with Crohn’s disease. (A) EMSA using nuclear extracts of purified
LP T cells from Crohn’s disease and control patients and a radiolabeled
T-bet DNA binding site. The location of the T-bet signal is indicated.
(B) Auto- and cross-competition assay. Specificity of the EMSA signal
obtained with the T-bet–binding site was shown by autocompetition
with unlabeled T-bet binding site, whereas cross-competition with unla-
beled SP-1,  E5, and AP-2 sites did not affect the signal. (C) Analysis of
T-bet expression in nuclear extracts of LP T cells (Crohn’s disease: n   3;
controls: n   2) by Western blot analysis. A high expression of T-bet was
observed in patients with Crohn’s disease but not control patients. A sec-
ond independent experiments with four patients per group showed simi-
lar results (data not shown). (D) Intracellular staining for STAT-1 and T-
bet by FACS® using LP cells from patients with Crohn’s disease or control
patients, as indicated. One representative experiment out of three is shown.1134 T-bet in Chronic Intestinal Inflammation
the inflamed intestine, we focused our attention on the ex-
pression of T-bet in several different animal models of T
cell–mediated animal models of chronic intestinal inflam-
mation previously shown to be associated with Th1 or Th2
subsets. Accordingly, we isolated nuclear proteins from T
cell enriched LPMCs in these colitis models and assessed
T-bet expression by EMSA and Western blot analysis (Fig.
3). T-bet was found to be strongly expressed in T cell en-
riched LP cells in the Th1-mediated colitis model observed
in SCID or RAG mice reconstituted with CD62L  CD4 
T cells. Time course studies showed that increased T-bet
expression in the colon occurred as early as 3 wk after cell
transfer before the onset of colitis (Fig. 3 A–C). Maximum
expression was noted 6 wk after cell transfer when the mice
started to develop colitis, although increased T-bet expres-
sion was also observed in the full-blown colonic inflamma-
tion seen at 12 wk after T cell transfer. Furthermore, in-
creased T-bet expression was consistently noted in two
additional Th1-mediated animal models of chronic intesti-
nal inflammation, namely colitis in IL-10–deficient mice
and colitis induced by the hapten reagent 2,4,6,-trini-
trobenzene sulfonic acid (TNBS) (Fig. 3 D). In contrast,
unchanged or lower levels of T-bet were detected in T cell
enriched LP cells in oxazolone colitis and TCR-  /    / 
associated colitis; two colitis models that are believed to be
mediated by IL-4–producing T cells and Th2 cells, respec-
Figure 3. Increased expression of T-bet in Th1- but not
Th2-mediated animal models of chronic intestinal in-
flammation A. Analysis of T-bet expression in C.B.-17
SCID mice reconstituted with 106 CD62L  CD4  T cells
from Balb/c mice. EMSA for T-bet using nuclear (NUC)
and cytoplasmic (CYT) extracts from spleen cells of unre-
constituted and CD62L  CD4  T cell reconstituted SCID
mice at indicated time points. SCID mice showed clinical
signs of colitis 8–9 wk after T cell transfer. (B) Supershift
assay for T-bet using nuclear extract from spleen cells of
SCID mice 6 wk after reconstitution with CD62L  CD4 
T cells from Balb/c mice. (C) Immunohistochemical anal-
ysis of the colon of SCID mice for T-bet expression at in-
dicated time points after reconstitution with CD62L 
CD4  T cells. T-bet expressing cells in the LP were noted
as soon as 3 wk after T cell transfer. (D) Expression of T-bet
in extracts from LPMCs in Th1- and Th2-mediated ani-
mal models of chronic intestinal inflammation. Whereas
increased T-bet expression by Western blot analysis was
noted in Th1-mediated models such as TNBS-induced
colitis in Balb/c mice and colitis in 4–12-wk-old IL-10
knockout mice, both oxazolone-induced colitis and
TCR-  /    /  colitis were associated with normal or
reduced T-bet expression in LPMCs.1135 Neurath et al.
tively (43, 47). These findings suggested that T-bet is po-
tentially a key regulator of the mucosal Th1/Th2 cytokine
balance in experimental colitis in vivo.
Retroviral Overexpression of T-bet Induces an Early Onset of
Severe CD62L  CD4  Th1 T Cell-mediated Colitis in SCID
Mice. We next determined the potential regulatory role
of T-bet in Th1-mediated colitis in vivo by retroviral over-
expression techniques. Accordingly, we analyzed the coli-
togenic potential of T cells after infection with a T-bet ret-
rovirus (Fig. 4 A). We observed in two independent
experiments that FACS®-sorted GFP  CD62L  double
positive CD4  T cells that were retrovirally transduced
with T-bet induced an earlier onset of severe colitis in
SCID mice compared with SCID mice reconstituted with
control transduced CD62L  T cells, as assessed by weight
loss curves (Fig. 4 A). Furthermore, SCID mice reconsti-
tuted with T-bet transduced T cells developed a massive
rectal prolapse as well as macroscopic signs of severe colitis
(Fig. 4 B and C). This phenotype suggested that the over-
expression of T-bet induced by retroviral gene transfer (Fig.
4 D) accelerates development of Th1-mediated chronic in-
testinal inflammation.
Mice Lacking T-bet (T-bet Knockout) Are More Susceptible to
Th2-mediated Colitis. Since the above data strongly sug-
gested that overexpression of T-bet plays an important role
in Th1-mediated colitis, we next analyzed the susceptibility
of mice in which the T-bet gene has been inactivated by
homologous recombination for T cell–mediated colitis. In
an initial series of studies, we determined whether T-bet–
deficient mice exhibited an altered susceptibility to Th2-
mediated colitis using the oxazolone-induced colitis model
that has previously been shown to be dependent on IL-4
production by T cells (47). As shown in Fig. 5, T-bet
knockout mice showed enhanced susceptibility to ox-
azolone-induced colitis compared with both wild-type lit-
termates and heterozygous T-bet mice, as shown by weight
curves (Fig. 5 A), macroscopic (Fig. 5 B), and histopatho-
logic (Fig. 5 C and D) criteria. This was accompanied by a
marked increase in IL-4 production by splenic CD3  T
cells, while IFN-  production by these cells was not signif-
icantly changed (Fig. 5 E).
To determine whether the observed increase in IL-4
production was responsible for the differences between
wild-type and T-bet knockout mice, we next administered
antibodies to IL-4 or control rat Ig to T-bet knockout mice
after oxazolone sensitization. It was found that antibodies
to IL-4 suppressed histologic colitis activity in oxazolone-
treated T-bet knockout mice (Fig. 5 F) strongly suggesting
that the protective role of T-bet in Th2-mediated colitis is
due to its direct or indirect regulation of IL-4 production.
T-bet Deficiency Protects from Th1-mediated Experimental
Colitis in an Adoptive Transfer Model Using CD62L  CD4 
T Cells. We next assessed the effects of T-bet deficiency
in Th1-mediated colitis induced by transfer of CD4 
CD62L  CD45Rbhigh T cells in SCID and RAG knock-
out mice (11, 17, 49). Whereas transfer of T-bet–express-
ing CD4  CD62L  T cells from wild-type mice resulted
in clinical and endoscopic signs of severe colitis, transfer of
T-bet /  CD4  CD62L  T cells failed to induce chronic
diarrhea, weight loss, rectal prolapse, and endoscopic signs
of colitis (Fig. 6 A, B, and D). Furthermore, transfer of
T-bet–deficient T cells resulted in a markedly reduced colitis
Figure 4. Overexpression of T-bet accelerates
development of Th1-mediated colitis. (A) Transfer
of T-bet transduced CD62L  CD4  T cells causes
rapid onset of colitis in SCID mice. Splenic CD4 
T cells from Balb/c mice were isolated and infected
with the T-bet retrovirus followed by FACS® sort-
ing for GFP/CD62L double positive T cells. GFP 
CD62L  CD4  T cells were then injected into
C.B.-17 SCID mice followed by monitoring of the
body weight at indicated time points after cell
transfer. Data represent mean values   SEM. Two
independent experiments are shown (right and
left). (B) Rectal prolapse upon reconstitution of
SCID mice with T-bet transduced (T-bet RV –
lower panel) and control transduced (CON-RV,
top panel) CD62L  T cells. The development of a
marked rectal prolapse was noted much earlier in
the former than in the latter group. (C) Macro-
scopic evidence of colitis in SCID mice reconsti-
tuted with T-bet transduced (T-bet RV, bottom
panel) and control transduced (CON-RV, top
panel) CD62L  T cells as compared with an unre-
constituted SCID mouse. (D) Western blot analysis
for T-bet expression in T-bet transduced versus
control transduced T cells before the T cell transfer.
As expected, retroviral infection with the T-bet vi-
rus led to much higher T-bet levels in the T cells as
compared with control infected T cells. The  -actin
staining served as loading control.1136 T-bet in Chronic Intestinal Inflammation
activity in mice reconstituted with CD62L  CD45Rbhigh
CD4  T cells in three independent experiments, as as-
sessed by macroscopic and histologic criteria (Fig. 6 C, E,
and F). This protective effect of T-bet deficiency on
CD62L  CD4  T cell–induced colitis was at least as pro-
nounced as that seen upon transfer of STAT-1-deficient
CD62L  CD4  T cells (histopathologic score: STAT-1 / 
reconstituted mice: 1.25   0.9 vs. T-bet /  reconsti-
tuted mice: 0.8   0.2). T cells from T-bet knockout mice
produced more IL-4 but less IFN-  before the T cell
transfer and, consistently, T-bet–deficient cells isolated
from reconstituted mice produced less IFN-  compared
with cells from both wild-type and T-bet heterozygous T
cell reconstituted mice (Fig. 6 G) suggesting that T-bet
deficiency suppresses proinflammatory cytokine produc-
tion by CD4  T cells in colitis in vivo. Interestingly,
CD4  CD62L  T cells from heterozygous T-bet mice
showed a marked variability to induce colitis in three in-
dependent experiments (Fig. 6 A-F), possibly due to a
threshold effect of T-bet expression on the colitogenic po-
tential of T cells.
T-bet Controls the Mucosal Balance between IFN-  and IL-4
Production by T Cell–enriched LP Cells in the Absence of Colito-
genic Stimuli. Since the above data suggested that T-bet
controls the balance between Th1 and Th2 cytokine pro-
duction by mucosal T lymphocytes in vivo, we next as-
sessed the structure of the LP and cytokine production by
LPMCs in mice lacking T-bet. We observed no macro-
scopic or histologic abnormalities in the small and large
bowel of T-bet heterozygous and T-bet knockout mice in
the absence of colitogenic stimuli (Fig. 7 A). To analyze
cytokine production by T cell enriched LPMCs from
Figure 5. T-bet–deficient
mice show enhanced susceptibil-
ity to oxazolone-induced colitis.
(A) T-bet wild-type (WT), het-
erozygous (HET) and knockout
mice (KO) were sensitized to
oxazolone followed by intrarec-
tal treatment with 1% oxazolone
in 50% ethanol after 1 wk and
monitoring of body weight (left).
Data are given as mean values  
SEM and represent six to eight
mice per group. Significant differ-
ences are indicated (*P   0.05).
In addition, ear thickness after
local oxazolone challenge was
determined in sensitized ani-
mals, as specified in Materials
and Methods (right). Data are
given as mean values   SEM
and represent six to eight mice
per group. No significant differ-
ences were noted. (B and C)
Macroscopic and histologic anal-
ysis of the colon of T-bet wild-
type and knockout mice 7 d after
intrarectal administration of ox-
azolone. One representative co-
lon per group is shown. There
was a marked inflammation of
the mucosa and submucosa in
T-bet–deficient mice associated
with edema, hypervasculariza-
tion, and ulcer formation (ar-
rowhead in bottom left panel)
that was more pronounced com-
pared with wild-type animals.
(D) Histopathologic assessment
of colitis activity in wild-type and T-bet–deficient mice given oxazolone.
Paraffin sections were scored in a blinded fashion, as described in Materials
and Methods. Data are given mean values   SEM and represent six to eight
mice per group. (E) Cytokine production by splenic CD3  T cells from
oxazolone-treated mice. T cells were stimulated with antibodies to CD3
and CD28 followed by analysis of culture supernatants by ELISA. Data rep-
resent four to eight mice per group and are given as mean values   SEM. A marked induction of IL-4 production was seen in T-bet–deficient mice. No
marked changes in IFN-  production by CD3  T cells were detected probably due to the fact that IFN-  production from T-bet–deficient CD8  T
cells is unimpaired (reference 47). (F) Anti–IL-4 treatment suppresses colitis activity in T-bet knockout mice. T-bet knockout mice were sensitized to
oxazolone followed by intraperitoneal administration of neutralizing anti–IL-4 antibodies and intrarectal oxazolone treatment. Colon samples were ob-
tained after 7 d followed by histopathologic analysis. Data represent three to four mice per group and are given as mean values   SEM.1137 Neurath et al.
Figure 6. T-bet deficiency protects from Th1-mediated colitis induced by
CD62L  CD4  T cell transfer in immunocompromised mice. Immunocom-
promised mice were reconstituted with CD62L  CD4  T cells from wild-type
and T-bet–deficient mice. In contrast to mice reconstituted with cells from
wild-type animals, mice injected with CD62L  CD4  T cells from T-bet
knockout mice showed neither wasting disease (A) nor rectal prolaps (B) and
macroscopic (C) or endoscopic (D) signs of inflammation. A shows weight data
(mean values   SEM) from one representative experiment out of three and represents data from five to six mice per group. C shows one representative
colon and spleen per group 8 wk after the T cell transfer. A significant reduction in endoscopic severity of colitis was noted in mice reconstituted with
CD62L  CD4  T cells lacking T-bet compared with cells from wild-type mice (D; P   0.05). In particular, no bleeding ulcers and erosions were noted
in the former mice that were frequently present after transfer of CD62L  CD4  T cells from wild-type mice (left panels in D). Furthermore, there was a
striking reduction of cell infiltration in the colon in mice reconstituted with T-bet–deficient T cells compared with mice reconstituted with T cells from
wild-type mice (E). Quantitative histopathologic assessment of colitis activity showed a highly significant (**P   0.01; ***P   0.0001) suppression of
both the inflammation and injury score in mice reconstituted with CD62L  CD4  T cells lacking T-bet compared with cells from wild-type mice (F).
Data were pooled from three independent experiments with at least five mice per group (n   19–23 per group) and are stated as mean values   SEM. In
addition, cytokine production by splenic CD4  T cells was assessed before and 8 wk after the T cell transfer. T cells were stimulated with anti-CD3 plus
CD28 antibodies and cytokine concentrations were determined by specific ELISA after 2 d. Data are shown as mean values   SEM (G).1138 T-bet in Chronic Intestinal Inflammation
T-bet–deficient mice and wild-type littermates, cells were
stimulated by anti-CD3 plus anti-CD28 for 48 h and cy-
tokine production in culture supernatants was determined
by ELISA (Fig. 7 B). It was found in two independent ex-
periments (purple and red bars) that T cell–enriched LPMCs
from T-bet knockout mice secreted lower levels of IFN- 
than cells from wild-type littermates in the absence of
colitogenic stimuli. In contrast, production of the Th2
type cytokines IL-4, IL-6, and IL-10 by T cell–enriched
LPMCs was augmented in T-bet–deficient animals com-
pared with wild-type mice. In particular, IL-4 production
by T-bet /  and T-bet /  LPMC was increased com-
pared with T-bet–expressing LPMCs from wild-type lit-
termates (Fig. 7 B). These changes in cytokine production
were seen using LPMCs from both the small and large
bowel suggesting that T-bet is a regulator of the mucosal
Th1/Th2 cytokine balance in the entire gut immune sys-
tem. Next, we assessed whether increased Th2 cytokine
production by LPMCs in T-bet knockout mice was asso-
ciated with evidence for activated IL-4 signaling in LP T
cells. There was increased GATA-3 expression in nuclear
extracts from LPMC of T-bet–deficient mice, as shown
by both gel retardation assays and Western blot analysis
(Fig. 7 C), consistent with an increased presence of Th2
effector T cells in the mucosa of T-bet knockout mice.
T-bet Deficient Regulatory CD62L  CD4  T Cells Show
Enhanced Protective Functions in Th1-mediated Colitis and Ex-
hibit Increased TGF-  Production and Signaling. Since the bal-
ance  between IFN-  and TGF-  appears to regulate
chronic intestinal inflammation (50), we focused in a final
series of studies on the effects of T-bet deficiency on TGF- 
production and signaling in T cells and the effect of
TGF-  on T-bet levels. We observed that treatment of ac-
tivated T cell–enriched LPMCs with TGF-  but not IL-4
suppressed T-bet expression suggesting a reciprocal rela-
tionship between T-bet and TGF-  levels (Fig. 8 A). Fur-
thermore, we found that T cell enriched LPMC in T-bet
knockout mice produced increased amounts of TGF- 
compared with cells from wild-type littermates (Fig. 8 B).
This increased production of TGF-  in the absence of
T-bet could be important for the regulatory function of
T-bet in colitis, since TGF-  production by T cells has
been recently suggested to play a key role in suppressing
chronic intestinal inflammation. In intestinal inflammation,
TGF-  is mainly produced by a unique population of reg-
ulatory CD25  CD45RBlow CD62L  CD4  T cells that
have been shown to suppress colitis activity in SCID mice
when cotransferred with CD4  CD62L  T cells (17).
Furthermore, at least in the spleen IL-4–producing T cells
have been shown to produce high amounts of TGF-  in
secondary cultures (51).
Interestingly, we observed that both splenic CD62L 
and CD62L  CD4  T cells from healthy mice expressed
large amounts of nuclear T-bet by Western blot analysis,
whereas splenic CD25  cells showed lower amounts of nu-
clear T-bet expression (Fig. 8 C). Furthermore, CD62L 
CD45RBlow CD4  T cells from T-bet knockout mice
showed decreased expression of Smad7, an inhibitory Smad
protein that is induced by IFN-  and suppresses TGF- 
signaling in T cells, compared with cells from wild-type
mice. Consistently, splenic T-bet /  CD4  T cells exhib-
ited increased nuclear Smad3 expression compared with
T-bet–expressing CD62L  CD4  T cells indicative of en-
hanced TGF-  signaling (Fig. 8 D). Based on these find-
ings on the enhanced production of TGF-  and increased
TGF-  signaling in T cells in the absence of T-bet, we
Figure 7. Changes in Th1 and Th2 cytokine production by LP cells in
T-bet–deficient mice. (A) Histologic analysis of the large bowel of T-bet
knockout mice (KO), heterozygous mice (HET), and wild-type litter-
mates (WT). There was no evidence for colitis in T-bet–deficient ani-
mals. Similarly, no evidence of intestinal inflammation was observed in
the small bowel (data not shown). (B) T cell–enriched LPMCs were iso-
lated from the small and large bowel of wild-type (WT) and T-bet–defi-
cient (KO) mice as well as from heterozygous (HET) mice and stimulated
with antibodies to CD3 and CD28. Supernatants were taken after 48 h
and analyzed for cytokine content by specific ELISA. Two representative
experiments (experiment 1: red bars; experiment 2: purple bars) out of
four are shown. (C) Western blot analysis and EMSA analysis for GATA-3
expression in nuclear extracts of LPMC from wild-type and T-bet–defi-
cient mice. There was an increased expression of GATA-3 in LPMCs
from T-bet knockout mice. The staining for  -actin and the EMSA for
SP1 served as loading controls.1139 Neurath et al.
then analyzed the potential regulatory capacity of CD62L 
CD4  T lymphocytes from wild-type, T-bet heterozy-
gous, and T-bet knockout mice to suppress colitis induced
by T-bet–expressing CD62L  CD4  T cells. Cotransfer of
regulatory CD62L  CD4  T cells plus naive CD62L 
CD4  T cells from T-bet–expressing wild-type mice led to
less severe colitis compared with mice reconstituted with
CD62L  CD4  T cells confirming a protective role for this
T cell subset in vivo (Fig. 8 E), as described previously by
others (17). Moreover, cotransfer of T-bet–deficient regu-
latory CD62L  CD4  T cells caused a more pronounced
protective effect on CD62L  CD4  T cell–mediated colitis
compared with regulatory CD62L  cells from wild-type
mice (Fig. 8 E). This finding was associated with an in-
creased production of TGF-  by LP T cells from reconsti-
tuted mice and by a relative expansion of the number of
CD4  CD25  T cells in the spleen of reconstituted mice
(Fig. 8 F and G).
Discussion
The balance between pro and antiinflammatory cyto-
kines secreted by T cells has been recently suggested to be a
major regulatory factor for both the initiation and perpetu-
ation of IBD. In particular, the balance between IFN- /
IL-4 and TGF-  activity appears to regulate chronic intes-
tinal inflammation (43, 50, 52). In this study, we have
identified T-bet as a key transcription factor that deter-
mines the mucosal cytokine balance in experimental colitis
in vivo. In an initial series of studies, we demonstrated that
T-bet is expressed in the nuclei of LP T cells in Crohn’s
disease but not in ulcerative colitis and control patients. We
then took advantage of genetically altered strains of mice
which overexpress or lack T-bet to uncover a critical role
for this factor in murine IBD. We studied both Th1- and
Th2-mediated models of IBD using both T-bet overex-
pressor transgenic and T-bet–deficient mice as well as
adoptive transfer of T-bet–transduced and T-bet–deficient
T cells. These studies revealed that T-bet–deficient T cells
fail to induce Th1-mediated colitis in an adoptive transfer
model of colitis while IL-4–mediated colitis is enhanced in
T-bet–deficient mice. Conversely, overexpression of T-bet
resulted in an earlier onset of severe Th1-mediated IBD.
Finally, we showed that regulatory T cells from T-bet–
deficient mice exhibit an enhanced protective capacity in
the context of Th1-mediated chronic intestinal inflamma-
tion most likely caused by increased TGF-  production
and signaling. Thus, these data unequivocally identify
T-bet as a master switch for the regulation of T cell–medi-
ated colitis in vivo.
Figure 8. The enhanced protective capacity of CD62L  CD4  T cells
from T-bet knockout mice is associated with increased production of
TGF-  and TGF-  signaling. (A) TGF-  downregulates T-bet expression
in T cell–enriched LPMCs. Cells were cultured in the presence of anti-
bodies to CD3 and CD28 with or without recombinant IL-4 and TGF- 
(1 ng/ml). Cellular extracts were made after 48 h and analyzed for the ex-
pression of T-bet and  -actin by Western blot analysis. (B) TGF-  pro-
duction by T cell–enriched LPMCs from wild-type (WT), T-bet het-
erozygous (HET), and T-bet knockout (KO) mice in the absence of
colitogenic stimuli. Cells were stimulated with antibodies to CD3 plus
CD28 and supernatants were analyzed by ELISA. (C) T-bet expression in
splenic CD25 , CD62L , CD4 , and CD62L  CD4  T cells from
healthy wild-type mice. Cytoplasmic (CYT) and nuclear (NUC) extracts
from these cells were isolated and analyzed for T-bet expression by West-
ern blotting. (D) Evidence for increased TGF- –mediated signaling in
T-bet–deficient CD4  T cells. CD4  T cells from wild-type and T-bet
knockout mice were stimulated with anti-CD3 plus anti-CD28 and
rIFN-  for 12 h followed by protein extraction and Western blot analysis.
Cellular extracts were analyzed for Smad7 expression whereas nuclear and
cytoplasmic extracts from CD4  T cells were analyzed for Smad3 levels.
(E) Inflammation score of mice reconstituted with CD62L  CD4  T
cells from wild-type mice and CD62L  CD4  T cells from T-bet knock-
out mice (KO) and wild-type (WT) control mice. Data represent three to
four mice per group and are given as mean values   SEM. (F) FACS®
analysis of splenic CD4  T cells from mice reconstituted with CD62L 
CD4  T cells from wild-type mice plus CD62L  CD4  T cells from T-bet
knockout mice (KO) or wild-type (WT) control mice. One representative
experiment is shown. (G) TGF-  production by LPMCs from the above re-
constituted mice. Cells were stimulated with antibodies to CD3 plus CD28
in serum free medium and supernatants were collected after 3 d followed by
analysis of supernatants by ELISA. Data represent mean values   SEM.1140 T-bet in Chronic Intestinal Inflammation
The Functions of T-bet in T Cell–dependent Experimental
Colitis In Vivo Correlate with T-bet–induced Changes in the
Mucosal Th1/Th2 Cytokine Balance. Previous studies have
shown that both Th1 and Th2 type cytokines can cause
chronic intestinal inflammation (17, 43, 45). With regard
to Th1-mediated colitis both IFN-  and TNF appear to be
the major driving forces that imprint a Th1 phenotype
onto the mucosal immune response, while IL-4 has been
shown to mediate Th2-dependent colitis (49). In this
study, we have analyzed the expression and role of T-bet
in several Th1- (TNBS-colitis, IL-10 /  colitis, CD62L 
adoptive transfer system) and Th2- (oxazolone-colitis,
TCR /  colitis) mediated animal models of chronic intes-
tinal inflammation. We observed that T-bet is a critical fac-
tor for both the initiation and perpetuation of Th1-medi-
ated colitis in an adoptive transfer model, as shown by the
fact that T-bet–deficient CD62L  CD4  T cells failed to
induce Th1-mediated colitis in immunodeficient hosts,
whereas T-bet–overexpressing CD4  T cells induced a
more rapid onset of colitis and T-bet heterozygous T cells
resulted in an intermediate severity of colitis. This finding
could be due to T-bet–dependent induction of Th1 cyto-
kine production, as LP T cells from mice reconstituted
with T-bet–deficient CD62L  CD4  T cells produced low
amounts of IFN- . However, the protective effects of
T-bet deficiency in T cells on Th1-mediated colitis were at
least as good as those observed in STAT-1–deficient mice
that have been shown to elicit poor biological responses to
IFN-  and IFN-  but not IL-10 (38, 53). Interestingly, T
cells from IFN-  knockout mice are known to induce
Th1-mediated colitis upon transfer in immunocompro-
mised mice (54) suggesting that T-bet has important regu-
latory functions in Th1 cells outside its capacity to control
IFN-  production that are essential for the development of
Th1-mediated colitis. In any case, our data strongly suggest
that T-bet is a master control element in the development
of Th1-mediated disease.
In the absence of colitogenic stimuli T cell–enriched
LP cells from T-bet–deficient mice produced decreased
amounts of IFN-  but substantially increased amounts of
IL-4 compared with cells from wild-type littermates. This
effect of T-bet deficiency on IFN-  production by LP cells
is likely to be due to reduced IFN-  gene transcription,
since potential regulatory binding sites for T-bet have been
identified both in intronic regions of the IFN-  gene and
the IFN-  promoter and T-bet has been shown to transac-
tivate the IFN-  promotor in the EL4 T cell line (39). Re-
cent studies from Reiner and colleagues further reveal that
T-bet controls Th1 effector fate by regulating IL-12 2
chain expression and directing chromatin remodeling to
individual IFN-  alleles (55). Although T-bet inhibits IL-4
and IL-5 production by an IFN- –independent mecha-
nism (39), the effect on IL-4 production could also be in
part due to the observed reduction of IFN-  in T-bet–
deficient LP cells, since IFN-  has been shown to inhibit
the IL-4/STAT-6 signaling pathway (56, 57) via STAT-1–
dependent induction of the silencer of cytokine signaling 1
(58). Consequently, IL-4–dependent or possibly T-bet–
cued activation of GATA-3 may result in Th2 T cell cy-
tokine production (27). In any case, the observed increased
production of IL-4 by LP T cells lacking T-bet appears to
be relevant for chronic intestinal inflammation, as T-bet
knockout mice exhibited an increase in IL-4 production
during oxazolone-induced colitis and antibodies to IL-4
were capable of suppressing such an effect. Thus, the lack
of T-bet expression in T lymphocytes is associated with an
enhanced susceptibility to IL-4–mediated chronic intestinal
inflammation. On the other hand, overexpression of T-bet
Figure 9. A regulatory role for T-bet in mucosal
cytokine production. T-bet controls Th1 and Th2
cytokine production in colitis and its levels are
downregulated by TGF- . On the other hand,
downregulation of T-bet is associated with increased
TGF-  levels possibly due to failure of T-bet–medi-
ated activation of Smad7.1141 Neurath et al.
in T cells results in a strikingly enhanced susceptibility for
Th1-mediated colitis. Since Crohn’s disease in humans
appears to be mediated by IL-12 driven mucosal effector
Th1 cells producing IFN-  and TNF-5, (45, 59) and
since we observed increased expression of T-bet in LP T
cells from patients with this disease, these data suggest that
a T-bet driven signaling pathway may be responsible for
the overproduction of proinflammatory Th1 cytokines in
this disease (10, 14, 16). Furthermore, the observed re-
duction in GATA-3 expression in this context presum-
ably leads to further changes in the balance between
T-bet and GATA-3 in Crohn’s disease and may account
for the reduced IL-4 production by LP T cells in this dis-
ease (10).
T-bet and TGF-  Production and Signaling in T Cells.
Regulatory T cells producing IL-10 or TGF-  have been
previously shown to mediate protective effects in Th1-
mediated colitis by suppressing the activity of T lympho-
cytes (17–19, 60). Interestingly, we observed that CD62L 
CD4  T cells from T-bet knockout mice exhibit a stronger
protective effect on CD62L  CD4  T cell–induced colitis
than the corresponding cell population from wild-type
mice. This observation appears to be related to differences
in TGF-  production and signaling, as CD4  T cells from
T-bet–deficient mice exhibited increased nuclear Smad3
expression. After binding of TGF-  to its receptor on T
cells, Smad3 is known to interact with the TGF-  receptor
I followed by importin-1 – and RanGTPase-mediated
import of Smad3 into the nucleus where it controls expres-
sion of TGF-  target genes (61). Interestingly, IFN-  has
been previously shown to inhibit TGF-  signaling by a
Jak1/STAT-1–mediated rapid activation of the synthesis of
the inhibitory Smad-7 protein, which in turn can prevent
the interaction of Smad3 with the TGF-  type I receptor
(60–64). Furthermore, Smad7 can form a complex with the
ubiquitin-ligase Smurf2 that targets the TGF-  receptor for
degradation (65). Thus, the reduced production of IFN- 
by splenic CD4  T cells and T cell–enriched LP cells in
T-bet–deficient animals may cause reduced expression of
Smad7 followed by increased TGF-  signaling via Smad3/4.
Consistent with this hypothesis, we observed that CD62L 
CD4  T cells from T-bet–deficient mice express reduced
levels of Smad7 compared with T cells from wild-type
mice. Since administration of neutralizing antibodies to
TGF-  is known to suppress the protective capacity of
CD62L  CD4  T cells on Th1-mediated colitis (17), these
data suggest that the enhanced regulatory capacity of
T-bet–deficient CD62L  CD4  cells is due to increased
TGF-  production and signaling. The enhanced TGF- 
production of T-bet–deficient T cells may even be aug-
mented after T cell transfer, as TGF-  has been demon-
strated to positively regulate its own production (51). The
relevance of a defect in TGF- 1 expression or TGF- –
mediated signaling via Smad3 for the mucosal immune sys-
tem has been shown by the observation that knockout
mice for these proteins develop T cell–mediated chronic
intestinal inflammation (52, 66–68). Finally, we observed
that TGF-  in turn downregulates T-bet expression in
mucosal cells suggesting a reciprocal relationship between
TGF-  and T-bet levels in T cells.
In summary, the present study identifies T-bet as a mas-
ter switch for T cell-mediated chronic intestinal inflamma-
tion and the regulation of protective immune responses by
TGF-  (Fig. 9). Thus, modulation of T-bet function ap-
pears to be an attractive target for local therapeutic inter-
vention in Th1-mediated chronic intestinal inflammation
such as is observed in Crohn’s disease.
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